Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27614131 | 0.89 | MAPT (0.43) | POLBSMN1; SMN2MAPK1MAPTALDH1A1 | |
| SCHEMBL13527456 | 0.87 | POLB (0.42) | POLBSMN1; SMN2MAPK1MAPTALDH1A1 | |
| SCHEMBL27614123 | 0.84 | ALDH1A1 (0.44) | POLBSMN1; SMN2MAPK1MAPTALDH1A1 | |
| SCHEMBL4776141 | 0.82 | POLB (0.43) | POLBSMN1; SMN2MAPTALDH1A1NPC1 | |
| SCHEMBL6097284 | 0.81 | POLB (0.39) | POLBSMN1; SMN2MAPK1MAPTALDH1A1 | |
| SCHEMBL4775385 | 0.81 | POLB (0.41) | POLBSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL4772531 | 0.80 | POLB (0.41) | POLBSMN1; SMN2MAPK1MAPTALDH1A1 | |
| SCHEMBL6219208 | 0.80 | POLB (0.39) | POLBSMN1; SMN2LMNA | |
| SCHEMBL3172845 | 0.80 | POLB (0.42) | POLBSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL563117 | 0.79 | POLB (0.38) | POLBMAPK1MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765071-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-07-07 | — | — | US | disclosed |
| US-9328110-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-8778963-B2 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070072893-A1 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072893-A1 | Substituted imidazo ring systems and methods | IL2, IRF3, EIF2AK2 | POLB 2587/4885SMN1; SMN2 3448/4885MAPK1 2400/4885 |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | POLB 1872/4885SMN1; SMN2 3376/4885MAPK1 2906/4885 |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | IL2, IL4, IFNG | POLB 2945/4885SMN1; SMN2 3333/4885MAPK1 2086/4885 |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | POLB 1872/4885SMN1; SMN2 3376/4885MAPK1 2906/4885 |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | IFNG, IRF3, IDO1 | POLB 1131/4885SMN1; SMN2 3106/4885MAPK1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.